MX2016011852A - Composiciones y metodos para prevenir o tratar la disfuncion cronica del aloinjerto pulmonar (clad) y fibrosis pulmonar idiopatica (fpi). - Google Patents

Composiciones y metodos para prevenir o tratar la disfuncion cronica del aloinjerto pulmonar (clad) y fibrosis pulmonar idiopatica (fpi).

Info

Publication number
MX2016011852A
MX2016011852A MX2016011852A MX2016011852A MX2016011852A MX 2016011852 A MX2016011852 A MX 2016011852A MX 2016011852 A MX2016011852 A MX 2016011852A MX 2016011852 A MX2016011852 A MX 2016011852A MX 2016011852 A MX2016011852 A MX 2016011852A
Authority
MX
Mexico
Prior art keywords
polypeptide
seq
methods
amino acid
pulmonary fibrosis
Prior art date
Application number
MX2016011852A
Other languages
English (en)
Inventor
Lander Cynthia
Brophy Colleen
W Noble Paul
Original Assignee
Moerae Matrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moerae Matrix Inc filed Critical Moerae Matrix Inc
Publication of MX2016011852A publication Critical patent/MX2016011852A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)

Abstract

La invención descrita proporciona composiciones y métodos para la reducción de la disfunción del aloinjerto pulmonar después de un trasplante pulmonar y una fibrosis pulmonar severa caracterizada por la proliferación aberrante de fibroblastos y la deposición de matriz extracelular en un tejido de un sujeto. Los métodos comprenden administrar a un sujeto en necesidad de la misma una composición farmacéutica que comprende un componente de anticuerpo que comprende una cantidad terapéutica de un anticuerpo anti-CD44; y un componente inhibidor de MK2 que comprende una cantidad terapéutica de un polipéptido inhibidor de MK2 (MK2i) de la secuencia de aminoácidos YAPAAARQARAKALARQLGVAA (SEQ ID NO: 1) o por lo menos un péptido funcionalmente equivalente al dominio terapéutico de la misma seleccionado de un polipéptido de la secuencia de aminoácidos KALARQLAVA (SEQ ID NO: 8), un polipéptido de la secuencia de aminoácidos KALARQLGVA (SEQ ID NO: 9) y un polipéptido de la secuencia de aminoácidos KALARQLGVAA (SEQ ID NO: 1) o un equivalente funcional de la misma, y un portador farmacéuticamente aceptable.
MX2016011852A 2014-03-14 2015-03-12 Composiciones y metodos para prevenir o tratar la disfuncion cronica del aloinjerto pulmonar (clad) y fibrosis pulmonar idiopatica (fpi). MX2016011852A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461953438P 2014-03-14 2014-03-14
PCT/US2015/020263 WO2015138784A2 (en) 2014-03-14 2015-03-12 Compositions and methods for preventing or treating chronic lung allograft dysfunction (clad) and idiopathic pulmonary fibrosis (ipf)

Publications (1)

Publication Number Publication Date
MX2016011852A true MX2016011852A (es) 2017-05-09

Family

ID=54067793

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016011852A MX2016011852A (es) 2014-03-14 2015-03-12 Composiciones y metodos para prevenir o tratar la disfuncion cronica del aloinjerto pulmonar (clad) y fibrosis pulmonar idiopatica (fpi).

Country Status (12)

Country Link
US (1) US20150258192A1 (es)
EP (1) EP3116543A4 (es)
JP (1) JP6655547B2 (es)
KR (1) KR20160124236A (es)
CN (1) CN106456758A (es)
AU (1) AU2015229251A1 (es)
BR (1) BR112016021000A2 (es)
CA (1) CA2942517A1 (es)
MX (1) MX2016011852A (es)
RU (1) RU2016140332A (es)
SG (1) SG11201607627RA (es)
WO (1) WO2015138784A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017053952A1 (en) 2015-09-25 2017-03-30 Cedars-Sinai Medical Center Targeting fibroblast invasion for pulmonary fibrosis
WO2019070908A1 (en) 2017-10-03 2019-04-11 Cedars-Sinai Medical Center METHODS OF TARGETING THE PD1 PATHWAY OF THE IMMUNE CONTROL POINT FOR THE TREATMENT OF PULMONARY FIBROSIS
CN113906132B (zh) * 2019-05-30 2024-06-28 北京生命科学研究所 特发性肺纤维化的动物模型、其构建方法和用途
KR20230044446A (ko) * 2020-07-24 2023-04-04 브리스톨-마이어스 스큅 컴퍼니 급성 호흡기 장애의 치료 방법
CN112575074B (zh) * 2020-10-09 2022-12-27 中山大学 Nestin基因及蛋白在治疗器官纤维化中的应用
WO2022147172A1 (en) * 2020-12-30 2022-07-07 Briotech, Inc. Methods and compositions of aqueous hypobromous acid for the treatment and prevention of inflammatory conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087264A1 (en) * 2004-03-17 2005-09-22 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Cd44-targeting for reducing/preventing ischemia-reperfusion-injury
US7723336B2 (en) * 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20080199426A1 (en) * 2007-01-11 2008-08-21 Sukhatme Vikas P Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders
EP2696888B1 (en) * 2011-04-12 2018-12-05 Moerae Matrix, Inc., Compositions and methods for preventing or treating pulmonary fibrosis
US10232039B2 (en) * 2011-04-12 2019-03-19 Duke University Compositions and methods for the treatment of tissue fibrosis

Also Published As

Publication number Publication date
BR112016021000A2 (pt) 2017-10-03
JP6655547B2 (ja) 2020-02-26
EP3116543A4 (en) 2017-09-06
WO2015138784A3 (en) 2015-10-29
RU2016140332A (ru) 2018-04-16
SG11201607627RA (en) 2016-10-28
WO2015138784A2 (en) 2015-09-17
US20150258192A1 (en) 2015-09-17
KR20160124236A (ko) 2016-10-26
CN106456758A (zh) 2017-02-22
JP2017509633A (ja) 2017-04-06
CA2942517A1 (en) 2015-09-17
AU2015229251A1 (en) 2016-09-22
EP3116543A2 (en) 2017-01-18
RU2016140332A3 (es) 2018-10-11

Similar Documents

Publication Publication Date Title
MX2016011852A (es) Composiciones y metodos para prevenir o tratar la disfuncion cronica del aloinjerto pulmonar (clad) y fibrosis pulmonar idiopatica (fpi).
MX2020004969A (es) Composiciones y procedimientos para tratar cancer.
MX2017006372A (es) Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matrix extracelular.
MX2017004488A (es) Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso.
NZ630484A (en) Compositions and methods for treatment of metabolic disorders and diseases
MX359516B (es) Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular.
MX340014B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX342291B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX360208B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
WO2013013085A3 (en) Anti-fibrotic peptides and their use in methods for treating diseases and disorders characterized by fibrosis
RU2017119773A (ru) Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение
WO2011149964A3 (en) Methods for treating or preventing vascular graft failure
WO2009052489A3 (en) Novel inhibitors of mammalian tight junction opening
MX2019000346A (es) Metodos y composiciones para el tratamiento del cancer.
MX2019008949A (es) Agente terapeutico para cardiomiopatia, infarto al miocardio antiguo e insuficiencia cardiaca cronica.
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
MX2009010965A (es) Péptidos de tem8 y vacunas que los contienen.
MX2022005483A (es) Composiciones y uso de las mismas para tratar la enfermedad celiaca.
EP4306123A3 (en) Saposin-a derived peptides and uses thereof
WO2019094938A3 (en) Methods and compositions for the treatment of wounds
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
MX2017008505A (es) Composicion.
MX2016010852A (es) Anticuerpo anti-inhibidor de activador de plasminogeno 1 (pai-1) humano novedoso.